Diabetes Mellitus Control and Chronic Kidney Disease

Authors

  • Safaa Mohamed Matarid Department of Internal Medicine, Mediclinic Al Ain Hospital, heikh Khalifa Bin Zayed St - next to Choithrams Supermarket, Abu Dhabi - United Arab Emirates

DOI:

https://doi.org/10.54536/ajcp.v2i2.1612

Keywords:

Chronic Kidney Disease, End Stage Renal Stage, Albuminuria, Pharmacological Therapies

Abstract

Chronic kidney disease (CKD) is the rampant onset of diabetes and related complications; chronic kidney disorders and end-stage renal disease are progressing in more than 10% of the world population and mostly affect the elderly, women, minorities and patients with diabetes and hypersensitivity. The early stages of CKD are typically quiet; thus, many people are unaware they have the condition. Data for this review was gathered from Google Scholar, Scopus, PubMed, Elsevier, Cochrane, Sage, Medline, and Web of Science. Studies were selected from 2018-2023, using keywords such as Diabetes mellitus management, chronic kidney disease, microalbuminuria, target time in range, impaired fasting glucose, management ways, lifestyle modification, medication treatment, and diet control. Although blood glucose levels are too unpredictable to provide a reliable evaluation, measures reflecting long-term glycemic load are used instead. The results gathered after the review suggests that optimal glycemic control along with lifestyle medication and diet control contributes to better outcomes in individuals with DM, particularly for microvascular damage. While, HbA1c is the most well-known glycemic biomarker of long-term glycemic management. This suggests that effective treatments are progressing on progression.This review has discussed different CKD management parameters; the authors have discussed the disease’s treatment criteria and protocols, such as pharmacological therapies, lifestyle modifications, physical activities and insulin therapy and concluded that to avoid CKD, it’s critical to concentrate on underlying problems including hyperglycemia, hypertension, microalbuminuria, sedentary behaviour, and smoking. The occurrence of CKD can be reduced with changes in lifestyle, such as increased physical activity, nutritious food, and water consumption.

Downloads

Download data is not yet available.

References

Advani, A. (2020). Positioning time in range in diabetes management. Diabetologia, 63(2), 242-252.

Alkhatib, L., Diaz, L. A. V., Varma, S., Chowdhary, A., Bapat, P., Pan, H., Kukreja, G., Palabindela, P., Selvam, S. A., & Kalra, K. (2023). Lifestyle modifications and nutritional and therapeutic interventions in delaying the progression of chronic kidney disease: A review. Cureus, 15(2).

Association, A. D. (2022). Statistics about Diabetes. American Diabetes Association https://diabetes.org/about-us/statistics/about-diabetes#:~:text=Prevalence%20in%20seniors%3A%20The%20percentage,diagnosed%20with%20diabetes%20every%20year.

Beck, R. W., Bergenstal, R. M., Cheng, P., Kollman, C., Carlson, A. L., Johnson, M. L., & Rodbard, D. (2019). The relationships between time in range, hyperglycemia metrics, and HbA1c. Journal of Diabetes Science and Technology, 13(4), 614-626.

Bello, A. K., Nwankwo, E., & El Nahas, A. M. (2005). Prevention of chronic kidney disease: a global challenge. Kidney International, 68, 11-17.

Betônico, C. C., Titan, S. M., Correa-Giannella, M. L. C., Nery, M., & Queiroz, M. (2016). Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control. Clinics, 71, 47-53.

Beulens, J., Rutters, F., Rydén, L., Schnell, O., Mellbin, L., Hart, H., & Vos, R. (2020). Risk and management of pre-diabetes. European Journal of Preventive Cardiology, 26(2l), 47-54. https://doi.org/10.1177/2047487319880041

Chen, T. K., Knicely, D. H., & Grams, M. E. (2019). Chronic kidney disease diagnosis and management: a review. Jama, 322(13), 1294-1304.

Cole, J. B., & Florez, J. C. (2020). Genetics of diabetes mellitus and diabetes complications. Nature Reviews Nephrology, 16(7), 377-390.

Copur, S., Onal, E. M., Afsar, B., Ortiz, A., van Raalte, D. H., Cherney, D. Z., Rossing, P., & Kanbay, M. (2020). Diabetes mellitus in chronic kidney disease: biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality. Journal of Diabetes and its Complications, 34(11), 107707.

Dincer, N., Dagel, T., Afsar, B., Covic, A., Ortiz, A., & Kanbay, M. (2019). The effect of chronic kidney disease on lipid metabolism. International Urology and Nephrology, 51, 265-277.

Eknoyan, G., & Nagy, J. (2005). A history of diabetes mellitus or how a disease of the kidneys evolved into kidney disease. Advances in chronic kidney disease, 12(2), 223-229.

Erfanpoor, S., Etemad, K., Kazempour, S., Hadaegh, F., Hasani, J., Azizi, F., Parizadeh, D., & Khalili, D. (2021). Diabetes, Hypertension, and Incidence of Chronic Kidney Disease: Is There any Multiplicative or Additive Interaction? Int. J. Endocrinol Metab, 19(1), e101061. https://doi.org/10.5812/ijem.101061

Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Malyszko, J., Verhaar, M. C., Ekart, R., Vanholder, R., London, G., Ortiz, A., & Zoccali, C. (2018). Lipid management in patients with chronic kidney disease. Nature reviews nephrology, 14(12), 727-749. https://doi.org/10.1038/s41581-018-0072-9

Gabbay, M. A. L., Rodacki, M., Calliari, L. E., Vianna, A. G. D., Krakauer, M., Pinto, M. S., Reis, J. S., Puñales, M., Miranda, L. G., Ramalho, A. C., Franco, D. R., & Pedrosa, H. P. C. (2020). Time in the range: a new parameter to evaluate blood glucose control in patients with diabetes. Diabetology & Metabolic Syndrome, 12(1), 22. https://doi.org/10.1186/s13098-020-00529-z

Gburek, J., Konopska, B., & Gołąb, K. (2021). Renal Handling of Albumin—From Early Findings to Current Concepts. International Journal of Molecular Sciences, 22(11), 5809.

Goyal, R., & Jialal, I. (2018). Diabetes mellitus type 2.

Hahr, A. J., & Molitch, M. E. (2015). Management of diabetes mellitus in patients with chronic kidney disease. Clinical Diabetes and Endocrinology, 1(1), 1-9.

Hannan, M., Ansari, S., Meza, N., Anderson, A. H., Srivastava, A., Waikar, S., Charleston, J., Weir, M. R., Taliercio, J., & Horwitz, E. (2021). Risk factors for CKD progression: an overview of findings from the CRIC study. Clinical Journal of the American Society of Nephrology, 16(4), 648-659.

Hussain, S., Habib, A., Hussain, M. S., & Najmi, A. K. (2020). Potential biomarkers for early detection of diabetic kidney disease. Diabetes Research and Clinical Practice, 161, 108082. https://doi.org/https://doi.org/10.1016/j.diabres.2020.108082

IDF. (2021). IDF Diabetes Atlas 2021. https://diabetesatlas.org/atlas/tenth-edition/

Kazancioğlu, R. (2013). Risk factors for chronic kidney disease: an update. Kidney international supplements, 3(4), 368-371.

Kim, H., Park, S., Kwon, S. H., Jeon, J. S., Han, D. C., & Noh, H. (2020). Impaired fasting glucose and development of chronic kidney disease in a non-diabetic population: a Mendelian randomisation study. BMJ Open Diabetes Research and Care, 8(1), e001395.

Kovesdy, C. P. (2022). Epidemiology of chronic kidney disease: an update 2022. Kidney international supplements, 12(1), 7-11.

Koye, D., Shaw, J., Reid, C., Atkins, R., Reutens, A., & Magliano, D. (2017). Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. Diabetic Medicine, 34(7), 887-901.

Koye, D. N., Magliano, D. J., Nelson, R. G., & Pavkov, M. E. (2018). The global epidemiology of diabetes and kidney disease. Advances in chronic kidney disease, 25(2), 121-132.

Kurzhagen, J., Dellepiane, S., Cantaluppi, V., & Rabb, H. (2020). AKI: an increasingly recognised risk factor for CKD development and progression. Journal of Nephrology, 33(6), 1171-1187.

Lu, J., Ma, X., Zhang, L., Mo, Y., Lu, W., Zhu, W., Bao, Y., Jia, W., & Zhou, J. (2020). Glycemic variability modifies the relationship between time in range and haemoglobin A1c estimated from continuous glucose monitoring: a preliminary study. Diabetes Research and Clinical Practice, 161, 108032.

Mayeda, L., Katz, R., Ahmad, I., Bansal, N., Batacchi, Z., Hirsch, I. B., Robinson, N., Trence, D. L., Zelnick, L., & de Boer, I. H. (2020). Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Research and Care, 8(1), e000991.

Miller, W. G., & Jones, G. R. (2018). Estimated glomerular filtration rate; laboratory implementation and current global status. Advances in Chronic Kidney Disease, 25(1), 7-13.

Ohishi, M. (2018). Hypertension with diabetes mellitus: physiology and pathology. Hypertension Research, 41(6), 389-393.

Oshima, M., Shimizu, M., Yamanouchi, M., Toyama, T., Hara, A., Furuichi, K., & Wada, T. (2021). Trajectories of kidney function in diabetes: a clinicopathological update. Nature Reviews Nephrology, 17(11), 740-750.

Parving, H.-H., Persson, F., & Rossing, P. (2015). Microalbuminuria: a parameter that has changed diabetes care. Diabetes Research and Clinical Practice, 107(1), 1-8.

Persson, F., & Rossing, P. (2018). Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney International Supplements, 8(1), 2-7.

Peruchetti, D. B., Barahuna-Filho, P. F., Silva-Aguiar, R. P., Abreu, T. P., Takiya, C. M., Cheng, J., Pinheiro, A. A. S., Cebotaru, L., Guggino, W. B., & Caruso-Neves, C. (2021). Megalin-mediated albumin endocytosis in renal proximal tubules is involved in the antiproteinuric effect of angiotensin II type 1 receptor blocker in a subclinical acute kidney injury animal model. Biochimica et Biophysica Acta (BBA)-General Subjects, 1865(9), 129950.

Porta, M. (2020). Diabetes in ancient times: the long and winding road to insulin. In Unveiling Diabetes-Historical Milestones in Diabetology 29, 1-13. Karger Publishers.

Prasad, R. M., & Tikaria, R. (2022). Microalbuminuria. StatPearls Publishing, Treasure Island (FL). http://europepmc.org/abstract/MED/33085402

Prevention, C. F. D. C. a. (2020). World Diabetes Day. https://www.cdc.gov/globalhealth/infographics/diabetes/world-diabetes-day.html#:~:text=Today%20415%20Million%20people%20worldwide,a%20billion%20will%20have%20diabetes.

Raja, P., Maxwell, A. P., & Brazil, D. P. (2021). The potential of albuminuria as a biomarker of diabetic complications. Cardiovascular drugs and therapy, 35, 455-466.

Rodrigues, B. T., Vangaveti, V. N., Urkude, R., Biros, E., & Malabu, U. H. (2022). Prevalence and risk factors of lower limb amputations in patients with diabetic foot ulcers: a systematic review and meta-analysis. Diabetes & Metabolic Syndrome: clinical research & reviews, 102397.

Romagnani, P., Remuzzi, G., Glassock, R., Levin, A., Jager, K. J., Tonelli, M., Massy, Z., Wanner, C., & Anders, H.-J. (2017). Chronic kidney disease. Nature Reviews Disease primers, 3(1), 1-24.

Sagoo, M. K., & Gnudi, L. (2020). Diabetic nephropathy: an overview. Diabetic Nephropathy: Methods and Protocols, 3-7.

Seino, Y., Kuwata, H., & Yabe, D. (2016). Incretin‐based drugs for type 2 diabetes: focus on East Asian perspectives. Journal of diabetes investigation, 7, 102-109.

Shah, V. N., Snell-Bergeon, J. K., Demmitt, J. K., Joshee, P., Garcetti, R., Pyle, L., & Polsky, S. (2021). Relationship Between Time-in-Range, HbA1c, and the Glucose Management Indicator in Pregnancies Complicated by Type 1 Diabetes. Diabetes Technol Ther, 23(12), 783-790. https://doi.org/10.1089/dia.2021.0093

Sutherland, D. E., & Gruessner, R. W. (2020). History of pancreas transplantation. In Transplantation, Bioengineering, and Regeneration of the Endocrine Pancreas 5-27. Elsevier.

Tong, L., & Adler, S. G. (2018). Diabetic kidney disease. Clinical Journal of the American Society of Nephrology, 13(2), 335-338.

Vigersky, R. A., & McMahon, C. (2019). The relationship of haemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technology & therapeutics, 21(2), 81-85.

Webster, A. C., Nagler, E. V., Morton, R. L., & Masson, P. (2017). Chronic kidney disease. The Lancet, 389(10075), 1238-1252.

Williams, J. K. Y. (2017). Management strategies for diabetic kidney disease and chronic kidney disease in diabetes. Nursing Clinics, 52(4), 575-587.

Winocour, P. (2018). Diabetes and chronic kidney disease: an increasingly common multi‐morbid disease needing a paradigm shift in care. Diabetic Medicine, 35(3), 300-305.

Wright, E. E., Jr., Morgan, K., Fu, D. K., Wilkins, N., & Guffey, W. J. (2020). Time in Range: How to Measure It, How to Report It, and Its Practical Application in Clinical Decision-Making. Clin Diabetes, 38(5), 439-448. https://doi.org/10.2337/cd20-0042

Yoo, J. H., & Kim, J. H. (2020). Time in the range from continuous glucose monitoring: a novel metric for glycemic control. Diabetes & metabolism journal, 44(6), 828-839.

Yu, E. S., Hong, K., & Chun, B. C. (2020). Incidence and risk factors of vascular complications in people with impaired fasting glucose: a national cohort study in Korea. Scientific Reports, 10(1), 19504. https://doi.org/10.1038/s41598-020-76661-7

Downloads

Published

2023-05-13

How to Cite

Safaa, M. M. (2023). Diabetes Mellitus Control and Chronic Kidney Disease. American Journal of Chemistry and Pharmacy, 2(2), 9–14. https://doi.org/10.54536/ajcp.v2i2.1612